Literature DB >> 16033706

A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs.

Scott A Melville1, Carmen L Wilson, Chiu S Chiang, Virginia P Studdert, Frode Lingaas, Alan N Wilton.   

Abstract

Neuronal ceroid lipofuscinosis (NCL) is a neurodegenerative disease found in Border collie dogs, humans, and other animals. Disease gene studies in humans and animals provided candidates for the NCL gene in Border collies. A combination of linkage analysis and comparative genomics localized the gene to CFA22 in an area syntenic to HSA13q that contains the CLN5 gene responsible for the Finnish variant of human late infantile NCL. Sequencing of CLN5 revealed a nonsense mutation (Q206X) within exon 4 that correlated with NCL in Border collies. This truncation mutation should result in a protein product of a size similar to that of some mutations identified in human CLN5 and therefore the Border collie may make a good model for human NCL. A simple test was developed to enable screening of the Border collie population for carriers so the disease can be eliminated as a problem in the breed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033706     DOI: 10.1016/j.ygeno.2005.06.005

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  31 in total

1.  [NCL in animal models].

Authors:  K Rüther
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

Review 2.  Large animal models for Batten disease: a review.

Authors:  Krystal Weber; David A Pearce
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

3.  A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.

Authors:  Natalie A Villani; Garrett Bullock; Jennifer R Michaels; Osamu Yamato; Dennis P O'Brien; Tendai Mhlanga-Mutangadura; Gary S Johnson; Martin L Katz
Journal:  Mol Genet Metab       Date:  2019-04-17       Impact factor: 4.797

Review 4.  Canine epilepsy genetics.

Authors:  Kari J Ekenstedt; Edward E Patterson; James R Mickelson
Journal:  Mamm Genome       Date:  2011-10-30       Impact factor: 2.957

5.  Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.

Authors:  Rebecca E H Whiting; Jacqueline W Pearce; Leilani J Castaner; Cheryl A Jensen; Rebecca J Katz; Douglas H Gilliam; Martin L Katz
Journal:  Exp Eye Res       Date:  2015-02-16       Impact factor: 3.467

6.  A mutation in canine PPT1 causes early onset neuronal ceroid lipofuscinosis in a Dachshund.

Authors:  Douglas N Sanders; Fabiana H Farias; Gary S Johnson; Vivian Chiang; James R Cook; Dennis P O'Brien; Sandra L Hofmann; Jui-Yun Lu; Martin L Katz
Journal:  Mol Genet Metab       Date:  2010-04-24       Impact factor: 4.797

Review 7.  Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions.

Authors:  Martin L Katz; Eline Rustad; Grace O Robinson; Rebecca E H Whiting; Jeffrey T Student; Joan R Coates; Kristina Narfstrom
Journal:  Neurobiol Dis       Date:  2017-08-30       Impact factor: 5.996

8.  A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3.

Authors:  Tony Frugier; Nadia L Mitchell; Imke Tammen; Peter J Houweling; Donald G Arthur; Graham W Kay; Otto P van Diggelen; Robert D Jolly; David N Palmer
Journal:  Neurobiol Dis       Date:  2007-09-29       Impact factor: 5.996

Review 9.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

10.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.